Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$0.31 - $1.06 $11,997 - $41,022
38,700 Added 15.76%
284,300 $221,000
Q4 2022

Feb 13, 2023

BUY
$0.27 - $11.9 $3,645 - $160,650
13,500 Added 5.82%
245,600 $74,000
Q3 2022

Nov 14, 2022

SELL
$0.51 - $10.4 $1,275 - $26,000
-2,500 Reduced 1.07%
232,100 $117,000
Q2 2022

Aug 12, 2022

BUY
$0.57 - $1.22 $61,559 - $131,760
108,000 Added 85.31%
234,600 $134,000
Q1 2022

May 13, 2022

BUY
$0.93 - $1.29 $70,959 - $98,427
76,300 Added 151.69%
126,600 $163,000
Q4 2021

Feb 11, 2022

BUY
$1.14 - $1.58 $57,341 - $79,474
50,300 New
50,300 $57,000
Q2 2021

Aug 13, 2021

SELL
$1.56 - $2.26 $245,700 - $355,949
-157,500 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$1.77 - $2.98 $303,593 - $511,135
-171,522 Reduced 52.13%
157,500 $290,000
Q4 2020

Feb 10, 2021

BUY
$1.58 - $3.64 $519,854 - $1.2 Million
329,022 New
329,022 $721,000
Q1 2020

May 14, 2020

SELL
$1.15 - $5.74 $49,494 - $247,043
-43,039 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$2.25 - $6.99 $96,837 - $300,842
43,039 New
43,039 $231,000

About Hepion Pharmaceuticals, Inc.


  • Ticker HEPA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,229,600
  • Market Cap $51.8M
  • Description
  • Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...
More about HEPA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.